Emyria raises AU$5 Mn to support drug registration, product portfolio expansion


  • Emyria has received firm commitments in a well-supported placement to raise AU$5 million.
  • The Company will use these funds to advance drug development and develop its product pipeline.
  • The proceeds would also support the initiation of psychedelic-assisted therapy clinical trial in partnership with Mind Medicine Australia.

ASX-listed data-backed drug development company Emyria Limited (ASX:EMD) announced that it had secured AU$5 million placement aimed at advancing drug registration and expanding its product pipeline.

While the ASX200 was down during the afternoon session, a few ASX-listed healthcare shares were performing well, trading in the green zone. These stocks include Ecofibre Limited (ASX:EOF), up 9.999%, 1ST Group Limited (ASX:1ST), up 9.523%, and IDT Australia Limited (ASX:IDT), up 6.060% (At AEST 1:14 PM).

DO READ: ASX 200 Today: Why All Sectoral Indices Are Taking a Tumble

Let us discuss Emyria’s announcement in detail-

Emyria secures AU$5 Mn in a well-supported placement

On 21 April 2021, Emyria Limited reported that it had received firm commitments from its sophisticated as well as strategic investors in a well-supported placement.

Source: Copyright © 2021 Kalkine Media Pty Ltd

The Company disclosed that the strategic focus behind the placement was to register new treatments that are backed by the unique clinical data and intellectual property (IP) of Emyria.

With this placement, the Company will issue 28.57 million new ordinary shares at a per-share price of AU$0.175 together with a 1 for 2 free attaching unlisted option exercisable at AU$0.35 with an expiry date two years from the issue date.

Dr Michael Winlo, Emyria’s Managing Director, said:

ALSO READ: ASX 200: Will COVID-19 concerns weigh on the market today?

Use of Funds

Emyria will use the funds of the Placement for-

Registration Support

With funds raised from the Placement, EMD is well-positioned to obtain current milestones related to its registration plans for EMD-003, which is targeting mental health concerns with capsule technology with partner Cann Group (ASX:CAN), and EMD-004, focussing on the Emyria’s IBS (irritable bowel syndrome) treatment under development.

Expansion of the global pipeline

The funds raised will also allow EMD to refine the regulatory strategy to register its pipeline products with the US FDA.

It will further exploit Emyria Data to generate additional IP and insights to support the launch of additional drug development programs for new indications that are under-served.

Furthermore, the Company will use these funds for:

  • The advancement of EMD-003 and EMD-004 pivotal clinical trials, an important milestone towards registration with the Therapeutic Goods Administration (TGA).
  • Defining the US Food Drug and Administration (FDA) regulatory pathways for EMD’s growing drug development
  • Initiation of psychedelic-assisted therapy clinical trial scoping in partnership with Mind Medicine Australia. The intention is to boost the clinical evidence behind the safe and appropriate use of these new treatments.
  • Providing support for further data analysis and intellectual property filing based on Emyria Data before additional drug development programs for new diseases.

Stock Information: On 21 April 2021, EMD shares were trading at AU$0.190, up by 5.001% at AEST 1:19 PM.

DID YOU KNOW: Emyria (ASX:EMD) to offer digital health monitoring services in WA

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK